Background The angiotensin‐receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was
shown to be superior to the angiotensin‐converting enzyme inhibitor enalapril in terms of …

Heart failure (HF) is a complex syndrome caused by a variety of structural or functional
cardiac abnormalities as a consequence of several involved pathophysiological pathways …

Background. Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF)
was shown to be superior to enalapril in reducing the risk of death and hospitalization for …

Aims The heart failure (HF) prognosis in older patients remains poor with a high 5‐years
mortality rate more frequently attributed to noncardiovascular causes. The complex interplay …

The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Background Sacubitril/valsartan has been shown to significantly reduce cardiovascular
mortality and hospitalizations due to heart failure in patients with reduced ejection fraction …

Cachexia is a multifactorial disease characterized by a pathologic shift of metabolism
towards a more catabolic state. It frequently occurs in patients with chronic diseases such as …

Purpose Sacubitril/valsartan reduced heart failure (HF) admissions and cardiovascular
mortality in the PARADIGM-HF trial. However, real-life studies are scarce comparing daily …

Background HF elderly patients are underrepresented in Sacubitril/Valsartan HF trials, and
the effect of S/V in real-life patients with advanced age is unknown. The aim of this study was …

Aims The angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …